Moderna's stock surged from $63 to $195 over two months following positive late-stage trial results for its personalized cancer vaccine (intismeran) developed with Merck. CEO Stéphane Bancel emphasized the company's diversified pipeline beyond COVID vaccines, citing five approved vaccines and a 50/50 oncology partnership. The rally reflects investor confidence in the company's mRNA platform expansion into cancer treatment.